Clinical Trial Update: A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy [Phase 2]

View source ↗

Summary

Phase II clinical study evaluating IBI310 or placebo with sintilimab for advanced cervical cancer after failure or intolerance to platinum-based therapy complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Advanced Cervical Cancer | Phase 2 | Status: COMPLETED